Abstract | Prostate cancer is considered a disease of older men (aged >65 years), but today over 10% of new diagnoses in the USA occur in young men aged ≤55 years. Early-onset prostate cancer, that is prostate cancer diagnosed at age ≤55 years, differs from prostate cancer diagnosed at an older age in several ways. Firstly, among men with high-grade and advanced-stage prostate cancer, those diagnosed at a young age have a higher cause-specific mortality than men diagnosed at an older age, except those over age 80 years. This finding suggests that important biological differences exist between early-onset prostate cancer and late-onset disease. Secondly, early-onset prostate cancer has a strong genetic component, which indicates that young men with prostate cancer could benefit from evaluation of genetic risk. Furthermore, although the majority of men with early-onset prostate cancer are diagnosed with low-risk disease, the extended life expectancy of these patients exposes them to long-term effects of treatment-related morbidities and to long-term risk of disease progression leading to death from prostate cancer. For these reasons, patients with early-onset prostate cancer pose unique challenges, as well as opportunities, for both research and clinical communities. Current data suggest that early-onset prostate cancer is a distinct phenotype-from both an aetiological and clinical perspective-that deserves further attention.
Introduction
Prostate cancer is the most common noncutaneous malignancy in American men, the incidence of which has increased since PSA screening was introduced in 1987. Specifically, the incidence of prostate cancer in young men (aged ≤55 years) increased by 5.7-fold from 5.6 to 32 cases per 100,000 person-years (95% CI 5.0-6.7) between 1986 and 2008. 1 During the same period, prostate cancer incidence increased across all age groups but the increase was more pronounced in young men ( Figure 1 ). In 2012, approximately 10% of the 241,740 men diagnosed with prostate cancer had early-onset disease, defined herein as onset at 55 years of age or younger. 1, 2 Although the median age of prostate cancer diagnosis decreased from 72 years in 1986 to 67 years in 2009, 1 this shift does not account for the steep rise in the incidence of early-onset prostate cancer. This information could have important implications given that existing data also suggest that relative survival (which is the comparison of the observed survival to the expected survival in a similarly aged group of patients of the same race over the same period) in patients with prostate cancer varies by age at diagnosis ( Figure 2) .
Today, most men diagnosed with prostate cancer have a favourable prognosis, with current estimates for 5-year and 10-year relative survival of 100.0% and 98.7%, respectively, based on data from men diagnosed with prostate cancer during 1994-2009 in Surveillance, Epidemiology, and End Results (SEER) registries. 3 These high survival rates indicate that the majority of prostate cancers are identified early in the natural history of the disease when treatment with curative intent is possible and advanced-stage disease makes up only a small proportion of total diagnoses. Moreover, young men with prostate cancer could have fewer comorbid conditions, which might otherwise complicate treatment choice or response, 4 and are also more likely to receive aggressive treatment than older men. 5, 6 Consistent with these data, several clinical studies report no significant difference in survival across age groups [7] [8] [9] [10] and no improvement in prognosis in the youngest age group (the specific age range varies by study) when compared with older men [11] [12] [13] [14] [15] [16] [17] after radical prostatectomy, [18] [19] [20] brachytherapy [21] [22] [23] or radiation therapy. [24] [25] [26] However, data from other studies consistently indicate a lower survival for the youngest patients 27, 28 than those in older age groups, except for men diagnosed at >80 years of age. 27, 28 Analysis of data from the US SEER cancer registries in 1994-2009, representing 28% of the population, reveal that men diagnosed with prostate cancer at ages 20-54 years have 5-year relative survival of 98%, whereas men diagnosed at ages 55-79 years have 5-year survival of 100%. 3 The notion that young age (≤55 years) at onset of prostate cancer is associated with worse prognosis than diagnosis at an older age was also reported during the pre-PSA era in several early European and US studies, 7, 8, 11, 12, 27, [29] [30] [31] some of which included large population-based cancer registry cohorts in the USA, 31 Sweden, 7 and Scotland. (8) (9) (10) or locally advanced prostate cancer at diagnosis, young men had particularly poor prognoses. 32 Specifically, among men diagnosed with stage IV cancer, those aged 35-44 years had an approximately 1.5-fold greater risk of prostate-cancer-specific mortality than men aged 65-74 years. Similarly, men diagnosed with high-grade tumours (Gleason score 8-10) at ages 35-44 years were 1.4 times more likely to die of prostate cancer than men with high-grade tumours aged 65-74 years at diagnosis. 32 Young men diagnosed with both high-grade and stage IV disease also had an increased risk of prostate-cancer-specific mortality compared with older men, but these data were not statistically significant. 32 Similar results were previously reported in a European study, 27 which altogether suggest that the observed poor prognosis in some men with early-onset prostate cancer can be attributed to severe disease, that is advanced-stage or high-grade at d iagnosis or both.
Many other clinical studies on survival of patients with prostate cancer (or on surrogate markers of survival such as biochemical recurrence) after treatment with curative intent have focused on data from men with organconfined or early-stage disease who were eligible for such therapies. [18] [19] [20] [21] [22] [23] [24] [25] [26] As a result, these studies would probably not have included data from young men with high-grade or metastatic tumours. Thus, in most clinical studies of prostate cancer comparing outcomes between young and old men, data from the early-onset cases, which is shown to be associated with the worst prognoses than all other age groups, except >80 years, 27 are under-represented or excluded completely.
Modelling early-onset prostate cancer
The unexpectedly poor prognosis of advanced-stage early-onset prostate cancer supports the idea that a new clinical subtype might exist in the subset of men with early-onset prostate cancer. The diagnosis of prostate cancer at a young age naturally selects for morerapidly growing or aggressive tumours. Figure 3 shows the natural history of prostate cancer from initiation to detection either by screening in asymptomatic men or by presentation of clini cal symptoms, eventually leading to metastasis and death. The tumour latency period is defined as the time when the tumour exists but is not detected. During this period the tumour attains a detectable size. The latency period starts at tumour onset and ends at diagnosis by screening or clinical symptoms. The term 'sojourn period' is used to refer to latency time in an unscreened population. In young men with prostate cancer, the latency time is generally shorter than in older men. For example, prostate cancer that begins to grow at 40 years of age and is diagnosed at age 41 through either prostate cancer screening or clinical symptoms will have progressed to a detectable state in 1 year. By comparison, prostate cancer that begins to grow at age 40 and is diagnosed at age 68 would have taken three decades to attain detection. The fact that the latency time for prostate cancer in young men is shorter than that in older men does not mean that rapidly-growing tumours do not exist in older men. However, it suggests that aggressive tumours more commonly occur in early-onset prostate cancer.
In prostate cancer, the prevalence of screening is a key determinant of the duration of the latency period. Several statistical models developed for the National Cancer Institute's Cancer Intervention and Surveillance Modeling Network (CISNET) [33] [34] [35] provide quantitative measures of the association between US screening patterns and prostate cancer incidence. The model provides estimates of the average latency time, by age and year of diagnosis ( Figure 4) . In men over 70 years of age, the latency time can reach up to 10 years, but men diagnosed with prostate cancer before age 50 years tend to have mean latency times <2 years, with progressively shorter latency periods in younger men.
In the late 1980s, the estimated latency time declined sharply following the introduction of PSA screening, as screening advanced the diagnosis of prostate cancer to an earlier point in its natural history. 34 The tumour latency period was shortened further in men over 55 years of age at diagnosis compared with younger men and was increasingly reduced with advancing age, whereby the biggest reduction in latency occurred in men in the oldest age group (>80 years) ( Figure 4 ).
The differential effect of PSA screening on latency time across age groups could be partially due to 'length bias' , which refers to the tendency for screening to preferentially detect slow-growing tumours over fast-growing tumours with shorter preclinical asymptomatic phases than slow-growing ones. 36 As a consequence, screeningdetected tumours are predisposed to slow-growing or indolent cancers, and the fastest growing tumours in
Key points
■ The incidence of prostate cancer in young men (aged ≤55 years) has increased sharply over the past two decades, making early-onset prostate cancer an important emerging issue for public health ■ Increased screening in young men could account for some, but not all, of the increase in incidence of early-onset prostate cancer ■ Advanced-stage and high-grade early-onset prostate cancer might be a distinct clinicopathological subtype with more rapid progression to disease-specific death than late-onset prostate cancer of similar stage and grade ■ Men with early-onset prostate cancer tend to have a greater genetic risk than their older peers, making this group an ideal resource for investigating genetic susceptibility to prostate cancer young men-with the shortest time frame available for detection before clinical symptoms appear-might be entirely missed by screening. With this context in mind, it is not surprising that the more-rapidly growing prostate tumours selected for by a young age at diagnosis tend to be associated with worse prognoses than the slower-growing tumours in old men.
Genetic risk
The three main risk factors for prostate cancer are old age (>60 years), 2 African American race, 1,37 and a family history. 38 A positive family history of prostate cancer is associ ated with a 2-3-fold greater risk of prostate cancer, and the risk is increased even more for young men with multiple affected relatives. 38, 39 The effect of family history on prostate cancer risk is not uniform across different age groups. In a study on a subcohort of the Health Professionals Follow-up Study, having a positive family history of prostate cancer was associated with a greater increase in risk among men under 65 years (RR = 2.3; 95% CI 2.0-2.6) than among their counterparts aged 65 years and over (RR = 1.7; 95% CI 1.5-1.9). 40 Other studies have reported similar findings. 41 This increased effect of family history on prostate cancer risk in young men follows directly from the estimates reported during the pre-PSA era. In one such report, Carter et al. 42 demon strated that hereditary prostate cancer accounts for a greater proportion of prostate cancer in early-onset cases than it does in men diagnosed at older ages. These results parallel those in other malignancies, such as breast, 43 colorectal, 44 and endometrial cancers, 45 which show that young age at cancer diagnosis is more likely to represent a hereditary p resentation of a tumour.
In addition to presence of a family history of prostate cancer, men diagnosed with early-onset prostate cancer are also more likely to carry a greater number of genetic variants that have been associated with an increased risk of prostate cancer in genome-wide association studies (GWAS) than older men. 46 Our research team 46 documented a statistically significant difference in the number of genetic variants between men diagnosed with early-onset prostate cancer (n = 12.4) and men diagnosed at older ages (n = 11.9, P = 1.7 × 10 -5 ). We also showed a significant overall increase in the cumulative number of risk alleles with decreasing age at diagnosis (P = 4.4 × 10 -5 ). 46 These data have been validated in another study. 47 The presence of an increased genetic component in early-onset prostate cancer is also consistent with the shorter time frame available for young men to accrue other exposures (such as infectious agents, 48 and dietary 49 or lifestyle p atterns 50 ) that might influence their risk of prostate cancer.
The identification of genes involved in prostate cancer development and susceptibility has proven to be challenging. 51 An issue remains in that the existing loci together explain only a small proportion of the familial clustering observed in the studies, leaving the question of whether additional prostate cancer genetic variants exist that could explain the 'missing' heritability un answered. 52 Rare variants with low-to-moderate penetrance are a | The age-adjusted incidence of prostate cancer increased dramatically during the late 1980s and early 1990s as a result of screening with serum PSA. Since then, incidence has decreased or stabilized among most age groups. Although prostate cancer in men aged ≤55 years (early-onset prostate cancer) represents only a small proportion of all men diagnosed with this disease, incidence in this group continues to rise. b | Change in incidence in men aged 50-55 years at diagnosis, for whom screening was commonly recommended by most medical organizations. Incidence in this group increased after PSA screening was introduced, but has stabilized to some extent since 1999. potential candidates, but current study designs are not well suited to identify these rare variants. 53 The availability of next-generation sequencing technology could help uncover these variants. 54 Indeed, next-generation sequencing data reveal the widespread existence of rare variants in the human population, whereby rare variants are more likely than common ones to affect the function of proteins. [55] [56] [57] Although most studies of prostate cancer genetics have usually included only a small number of men aged ≤55 years, the available evidence suggests that focusing efforts on these early-onset cases, which represent a population enriched for genetic susceptibility to prostate cancer, should provide the best opportunity to successfully identify new variants. The potential value of this approach has been illustrated by our discovery of a rare non synonymous single-nucleotide polymorphism (SNP), G84E or rs138213197, 58 in HOXB13, a transcription factor involved in early-onset prostate cancer development and differentiation 59 that has been implicated in androgen-independent prostate cancer growth. 60 Although the G84E allele was observed in unrelated men with prostate cancer, including those diagnosed at an old age (minor allele frequency [MAF] 0.6%), its expression was significantly enhanced in men with early-onset prostate cancer (MAF 2.2%), and particularly among those with a family history of prostate cancer (MAF 3.1%). 58 This variant was subsequently shown to be associated with both hereditary and sporadic prostate cancer in many independent study populations. [61] [62] [63] [64] [65] [66] [67] [68] Further research on early-onset prostate cancer could provide an opportunity to identify new genetic loci associated with increased risk for this disease.
Genetic testing
The discovery of around 70 genetic variants from GWAS, as well as the discovery of the HOXB13 G84E variant, has generated interest in the possibility of personalized genetic testing to identify individuals at a high risk of prostate cancer who might benefit from increased surveillance. [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] However, the clinical utility of this approach has been inhibited by the modest effect of most individual polymorphisms identified by GWAS on disease risk, which is usually 1.1-1.5-fold greater in carriers than non-carriers. 69 One way to overcome this limitation is to consider cumulative genetic burden as a count of risk alleles carried by each man. Generally, this method tends to strengthen the association between genetic burden and prostate cancer risk, although the magnitude of risk associated with each aggregate score can vary widely across study populations. Increasing the number of variants, as and when additional new risk alleles (such as HOXB13 G84E) are identified, is also expected to improve the performance of a genetic risk test. For example, in a Swedish case-control study, inclusion of additional SNPs to a genetic risk test did not substantially improve the positive predictive value of the test (that is, the accuracy of a positive test), but did increase the test sensitivity (that is, the ability of the test to correctly classify men diagnosed with prostate cancer). 79 Even when as many as 25 common prostate cancer genetic markers were considered in a large case-control study, 47 the area under the curve (AUC) only improved from 0.526 (with family history alone) to 0.642 (with family history and expression of SNPs), compared with the AUC for a single PSA test at >0.70 in a meta-analysis of 23 studies. 84 Rare alleles might be associated with increased penetrance (for example, HOXB13 G84E); however, they will affect only a small number of the population at risk and this limitation might be compounded when multiple rare alleles are considered simultaneously. Currently, no genetic risk model is available to qualify as a suitable discriminative test for prostate cancer.
Despite the current limitations of genetic testing for prostate cancer, overall data suggest that genetic risk prediction is more useful in younger men than in older men. Using data from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium, Lindstrom et al. 47 reported that the performance of an aggregate genetic risk score based on 25 common prostate cancer genetic markers was improved by testing in young men. The discriminative ability of the 25-SNP model increased significantly with decreasing age (P = 0.009), with better performance in men ≤60 years than in older age groups. 47 This finding was true for both a model using SNPs alone and a model that included SNPs and family history of prostate cancer in any first-degree relative. These results have important implications for the targeted application of genetic risk stratification among young men as a means to identify patients who can potentially benefit from early detection strategies and/or chemoprevention.
Future challenges and opportunities
As the urologist Willet F. Whitmore acknowledged in his famous quote, "Is cure necessary in those for whom it is possible, and is cure possible in those for whom it is neces sary?", 85 although many men are diagnosed with prostate cancer, not all of them benefit from treatment. In the PIVOT trial, the largest randomized trial conducted to date to evaluate the effectiveness of surgery versus observation for men with localized prostate cancer, the investigators reported no effect of radical prostatectomy on all-cause mortality or prostate-cancerspecific mortal ity after a median follow-up of 10 years. 86 Notably, no difference was observed in the results of the trial by age at diagnosis; however, only 75 of 731 participants were aged under 60 years, including four men under age 50 years. As the median age at diagnosis for prostate cancer is 68 years and the 5-year relative survival for prostate cancer over 98%, 1 many men in the trial might have succumbed to other causes of death before death from prostate cancer could occur. Young men with prostate cancer, however, are less likely to die from causes unrelated to their cancer diagnosis. The question, therefore, remains whether the lack of survival benefit with radical prostatectomy would hold true if a greater number of early-onset prostate cancer cases were included in the study.
The negative result of the PIVOT trial adds to other evidence that raise serious concerns about the ability to distinguish prostate tumours that will lead to metastatic disease and premature death from those that will not. 87, 88 Among American men, a considerable gap exists between the 16% (one in six men) lifetime risk of developing prostate cancer and the 3% (one in 33 men) lifetime risk of dying from it. 37 Clinical focus must be redirected toward patients who are more likely to have clinically significant tumours that will benefit from treatment, but this goal can only be accomplished through the development of a test that can identify men at risk of developing clinically significant prostate cancer. So far, despite extensive investigation, few genetic variants have been associated with aggressive prostate cancer that will lead to death. 89 The potential existence of a particularly aggressive clinical subtype within early-onset prostate cancer provides a unique opportunity to investigate the fundamental challenge in prostate cancer today: whether a specific genetic susceptibility to aggressive, rapidly-progressing prostate cancer exists. Although such a finding would benefit all men, those at risk of advanced-stage early-onset prostate cancer-who are among the least likely to benefit from traditional screening with PSA owing to the length bias-would e xperience the greatest benefit.
At present, the majority of men with early-onset prostate cancer are diagnosed with moderately-differentiated, organ-confined disease. 3 In a study of data from a large national disease registry called Cancer of the Prostate Strategic Urologic Research Endeavor, over 90% of men with organ-confined prostate cancer opted for curative treatment. 90 Furthermore, review of treatment choices revealed a clear preference for radical prostatectomy in men younger than age 65 years (79%) compared with older men (37%). 90 Studies on treatment decisions suggest that younger patients have different priorities and concerns compared with older men. For example, among men diagnosed with low-grade (Gleason score 6) prostate cancer, younger men (under age 50 years) placed a greater importance on sexual function after treatment than urinary function, 91 whereas in an older group of patients, fear of impotence was less important. 92 
Conclusions
Several features of early-onset prostate cancer present unique opportunities for genetic and clinical research in prostate cancer. Inherited prostate cancer susceptibility has a greater role in prostate cancer diagnosis in younger men than in older men and might indicate a richer group of cases for discovery of cancer susceptibility genes. In addition, studying prostate cancer in the youngest group of men under age 55 years could also lead Introduction of PSA screening in 1988, and its increased utilization in subsequent years, led to shortening of latency time as cancer is now detected earlier. The impact of screening is dramatic for older ages, but the change for younger patients is much smaller because their sojourn times (latency in the absence of screening) are shorter, and they are also more likely to be missed by screening. 34, 35 REVIEWS to further understanding and identification of the role of rare alleles, such as HOXB13 mutations and other genes with pleiotropic phenotypes that might contribute to the development of prostate cancer in young men. As the majority of young men diagnosed with prostate cancer tend to have low-grade, organ-confined tumours, these patients are likely to represent a unique group of cancer survivors who might experience treatment-related morbid ities as they will live for a longer period than their older peers.
Taken together, early-onset prostate cancer is a unique clinical entity, which is rising in incidence in the USA. As early-onset prostate cancer is associated more with
